BACKGROUND: Cyclooxygenase-2 (COX-2) is upregulated in pulmonary artery smooth muscle cells (PASMCs) during hypoxia and may play a protective role in the response of the lung to hypoxia. Selective COX-2 inhibition may have detrimental pulmonary vascular consequences during hypoxia. METHODS AND RESULTS: To investigate the role of COX-2 in the pulmonary vascular response to hypoxia, we subjected wild-type and COX-2-deficient mice to a model of chronic normobaric hypoxia. COX-2-null mice developed severe pulmonary hypertension with exaggerated elevation of right ventricular systolic pressure, significant right ventricular hypertrophy, and striking vascular remodeling after hypoxia. Pulmonary vascular remodeling in COX-2-deficient mice was characterized by PASMC hypertrophy but not increased proliferation. Furthermore, COX-2-deficient mice had significant upregulation of the endothelin-1 receptor (ET(A)) in the lung after hypoxia. Similarly, selective pharmacological inhibition of COX-2 in wild-type mice exacerbated hypoxia-induced pulmonary hypertension and resulted in PASMC hypertrophy and increased ET(A) receptor expression in pulmonary arterioles. The absence of COX-2 in vascular smooth muscle cells during hypoxia in vitro augmented traction forces and enhanced contractility of an extracellular matrix. Treatment of COX-2-deficient PASMCs with iloprost, a prostaglandin I(2) analog, and prostaglandin E(2) abrogated the potent contractile response to hypoxia and restored the wild-type phenotype. CONCLUSIONS: Our findings reveal that hypoxia-induced pulmonary hypertension and vascular remodeling are exacerbated in the absence of COX-2 with enhanced ET(A) receptor expression and increased PASMC hypertrophy. COX-2-deficient PASMCs have a maladaptive response to hypoxia manifested by exaggerated contractility, which may be rescued by either COX-2-derived prostaglandin I(2) or prostaglandin E(2).
BACKGROUND:Cyclooxygenase-2 (COX-2) is upregulated in pulmonary artery smooth muscle cells (PASMCs) during hypoxia and may play a protective role in the response of the lung to hypoxia. Selective COX-2 inhibition may have detrimental pulmonary vascular consequences during hypoxia. METHODS AND RESULTS: To investigate the role of COX-2 in the pulmonary vascular response to hypoxia, we subjected wild-type and COX-2-deficient mice to a model of chronic normobaric hypoxia. COX-2-null mice developed severe pulmonary hypertension with exaggerated elevation of right ventricular systolic pressure, significant right ventricular hypertrophy, and striking vascular remodeling after hypoxia. Pulmonary vascular remodeling in COX-2-deficient mice was characterized by PASMChypertrophy but not increased proliferation. Furthermore, COX-2-deficient mice had significant upregulation of the endothelin-1 receptor (ET(A)) in the lung after hypoxia. Similarly, selective pharmacological inhibition of COX-2 in wild-type mice exacerbated hypoxia-induced pulmonary hypertension and resulted in PASMChypertrophy and increased ET(A) receptor expression in pulmonary arterioles. The absence of COX-2 in vascular smooth muscle cells during hypoxia in vitro augmented traction forces and enhanced contractility of an extracellular matrix. Treatment of COX-2-deficient PASMCs with iloprost, a prostaglandin I(2) analog, and prostaglandin E(2) abrogated the potent contractile response to hypoxia and restored the wild-type phenotype. CONCLUSIONS: Our findings reveal that hypoxia-induced pulmonary hypertension and vascular remodeling are exacerbated in the absence of COX-2 with enhanced ET(A) receptor expression and increased PASMChypertrophy. COX-2-deficient PASMCs have a maladaptive response to hypoxia manifested by exaggerated contractility, which may be rescued by either COX-2-derived prostaglandin I(2) or prostaglandin E(2).
Authors: James P Butler; Iva Marija Tolić-Nørrelykke; Ben Fabry; Jeffrey J Fredberg Journal: Am J Physiol Cell Physiol Date: 2002-03 Impact factor: 4.249
Authors: T Minamino; H Christou; C M Hsieh; Y Liu; V Dhawan; N G Abraham; M A Perrella; S A Mitsialis; S Kourembanas Journal: Proc Natl Acad Sci U S A Date: 2001-07-10 Impact factor: 11.205
Authors: B W Fouty; B Grimison; K A Fagan; T D Le Cras; J W Harral; M Hoedt-Miller; R A Sclafani; D M Rodman Journal: Am J Respir Cell Mol Biol Date: 2001-11 Impact factor: 6.914
Authors: Y Hoshikawa; N F Voelkel; T L Gesell; M D Moore; K G Morris; L A Alger; S Narumiya; M W Geraci Journal: Am J Respir Crit Care Med Date: 2001-07-15 Impact factor: 21.405
Authors: Yan Cheng; Sandra C Austin; Bianca Rocca; Beverly H Koller; Thomas M Coffman; Tilo Grosser; John A Lawson; Garret A FitzGerald Journal: Science Date: 2002-04-19 Impact factor: 47.728
Authors: Xudong Yang; Karen K K Sheares; N Davie; Paul D Upton; Graham W Taylor; Jo Horsley; John Wharton; Nicholas W Morrell Journal: Am J Respir Cell Mol Biol Date: 2002-12 Impact factor: 6.914
Authors: Laura E Fredenburgh; Margarita M Suárez Velandia; Jun Ma; Torsten Olszak; Manuela Cernadas; Joshua A Englert; Su Wol Chung; Xiaoli Liu; Cynthia Begay; Robert F Padera; Richard S Blumberg; Stephen R Walsh; Rebecca M Baron; Mark A Perrella Journal: J Immunol Date: 2011-10-03 Impact factor: 5.422
Authors: Yi Jin; Thomas J Calvert; Bernadette Chen; Louis G Chicoine; Mandar Joshi; John Anthony Bauer; Yusen Liu; Leif D Nelin Journal: Am J Physiol Heart Circ Physiol Date: 2010-02-19 Impact factor: 4.733
Authors: Paul B Dieffenbach; Christina Mallarino Haeger; Anna Maria F Coronata; Kyoung Moo Choi; Xaralabos Varelas; Daniel J Tschumperlin; Laura E Fredenburgh Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-06-22 Impact factor: 5.464
Authors: Victoria N Parikh; Richard C Jin; Sabrina Rabello; Natali Gulbahce; Kevin White; Andrew Hale; Katherine A Cottrill; Rahamthulla S Shaik; Aaron B Waxman; Ying-Yi Zhang; Bradley A Maron; Jochen C Hartner; Yuko Fujiwara; Stuart H Orkin; Kathleen J Haley; Albert-László Barabási; Joseph Loscalzo; Stephen Y Chan Journal: Circulation Date: 2012-02-27 Impact factor: 29.690
Authors: Fei Liu; Christina Mallarino Haeger; Paul B Dieffenbach; Delphine Sicard; Izabela Chrobak; Anna Maria F Coronata; Margarita M Suárez Velandia; Sally Vitali; Romain A Colas; Paul C Norris; Aleksandar Marinković; Xiaoli Liu; Jun Ma; Chase D Rose; Seon-Jin Lee; Suzy A A Comhair; Serpil C Erzurum; Jacob D McDonald; Charles N Serhan; Stephen R Walsh; Daniel J Tschumperlin; Laura E Fredenburgh Journal: JCI Insight Date: 2016-06-02